Edwards Lifesciences (EW) Tops Q2 EPS by 8c; Lifts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Edwards Lifesciences (EW) PT, Estimates Lifted at Piper Jaffray Amid Solid Q2
July 29, 2015 9:02 AM EDTPiper Jaffray analyst Brooks West reiterated an Overweight rating and boosted estimates and his price target on Edwards Lifesciences (NYSE: EW) to $181.00 (from $170.00) following Q2 results.
West commented, "Edwards reported Q2 revenues of $616.8M, beating our Street high estimate of $615.5M and consensus... More



